Drug Discovery World
AUGUST 16, 2023
Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.
pharmaphorum
JANUARY 26, 2023
2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 7, 2022
Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. In April 2003, after its launch in October 1990, the project was completed, generating the first sequence of the human genome. The origins .
Drug Discovery World
MARCH 13, 2024
Singapore is also leading the way in genomics, having founded The Genome Institute of Singapore as far back as 2000. Dr Gokhale expands on the country’s leadership role: “Singapore is a great example of integration of genomic medicine in healthcare via population scale research.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. We also recently opened the Scientific Centre of Excellence for Genomic Insight at our Cambridge site.”
Roots Analysis
AUGUST 28, 2022
As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.
Drug Discovery World
OCTOBER 6, 2022
Jarret Glasscock , PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. . New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies.
Expert insights. Personalized for you.
52 
Let's personalize your content